Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of...
-
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
-
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
-
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
-
– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – Significant Clinical Progress for First-in-Class PKR...
-
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
-
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
-
– Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments – CAMBRIDGE, Mass. and NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) --...
-
– Treatment with Mitapivat Induced Hemoglobin (Hb) Increase of ≥1.0 g/dL in 12 of 13 (92%) Evaluable Patients, Including 4 of 4 (100%) α-Thalassemia Patients, During Weeks 4-12 – – 7 of 8 (88%)...
-
– 5 of 8 (63%) Efficacy Evaluable Patients Achieved a Hemoglobin Increase of ≥1.0 g/dL From Baseline – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients...